StockData
Ardelyx, Inc. logo

Ardelyx, Inc. (ARDX) stock

ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3058% below fair value
$3.18+0.11 (+3.58%)

Close on Nov 17, 2026Market cap $792.42MP/E –Yield –

Earnings

Ardelyx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 18, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$125.50M
+13.8% on a year earlier
EPS, Q3 FY2026
$0.00
$0.00 a year earlier
Latest guidance
Raised
Nov 3, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Ardelyx's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 18, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$125.50M+13.8%$0.00Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours––-$0.07Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026during market hours$94.47M+27.5%-$0.15Release
Q4 FY2025ended Dec 31, 2025Feb 19, 2026during market hours$125.22M+7.8%$0.00Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025during market hours$110.30M+12.3%$0.00Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025during market hours$97.70M+33.5%-$0.08Release
Q1 FY2025ended Mar 31, 2025May 1, 2025during market hours$74.10M+61.1%-$0.17Release
Q4 FY2024ended Dec 31, 2024Feb 20, 2025before the open$116.13M+237.9%$0.02Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024during market hours$98.20M+74.1%$0.00Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$73.20M+228.3%-$0.07Release
Q1 FY2024ended Mar 31, 2024May 2, 2024during market hours$46.00M+304.6%-$0.11Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Ardelyx's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenue guidance for IBSRELAFY2026$350.00M – $370.00M$410.00M – $430.00MRaisedNov 3, 2026
revenue guidance for IBSRELAFY2026$350.00M – $370.00M$410.00M – $430.00MRaisedAug 6, 2026
operating expense guidanceFY2026$500.00M–NewNov 3, 2026
OPEX guidanceFY2026$500.00M–NewAug 6, 2026
annual revenueFY2029$1.00B–NewFeb 19, 2026

Guidance vs results

The last range Ardelyx gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$270.00M – $275.00M$407.32MΣ4QAbove range

Guidance history

Every forecast Ardelyx put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026operating expense guidanceFY2026$500.00MNew
Nov 3, 2026revenue guidance for IBSRELAFY2026$350.00M – $370.00MRaised
Nov 3, 2026annual revenuelong-term$1.00B–
Nov 3, 2026revenue guidance for XPHOZAHFY2026$110.00M – $120.00MLowered
Aug 6, 2026OPEX guidanceFY2026$500.00MNew
Aug 6, 2026IBSRELA long-term guidancelong-term$1.00B–
Aug 6, 2026revenue guidance for IBSRELAFY2026$350.00M – $370.00MRaised
Aug 6, 2026revenue guidance for XPHOZAHFY2026$110.00M – $120.00MLowered
Apr 30, 2026IBSRELA revenueFY2026$410.00M – $430.00MNew
Apr 30, 2026XPHOZAH revenueFY2026$110.00M – $120.00MLowered
Feb 19, 2026annual revenueFY2029$1.00BNew
Feb 19, 2026revenue for IBSRELAFY2026$410.00M – $430.00MNew
Feb 19, 2026XPHOZAH revenueFY2026$110.00M – $120.00MLowered
Oct 30, 2025IBSRELA revenueFY2025$270.00M – $275.00MNew
Aug 4, 2025IBSRELA net sales revenueFY2025$250.00M – $260.00MRaised
May 1, 2025U.S. net product sales revenue for IBSRELAFY2025$240.00M – $250.00MReaffirmed
Feb 20, 2025U.S. net product sales revenue for IBSRELAFY2025$240.00M – $250.00MNew
Oct 31, 2024U.S. net product sales revenue for IBSRELAFY2024$145.00M – $150.00MRaised
Aug 1, 2024U.S. net product sales revenue for IBSRELAFY2024$140.00M – $150.00MReaffirmed
May 2, 2024U.S. net product sales revenue for IBSRELAFY2024$140.00M – $150.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ardelyx filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?